Ferry Lalezari

4.3k total citations · 2 hit papers
33 papers, 1.7k citations indexed

About

Ferry Lalezari is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Ferry Lalezari has authored 33 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pulmonary and Respiratory Medicine, 12 papers in Oncology and 10 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Ferry Lalezari's work include Lung Cancer Diagnosis and Treatment (11 papers), Radiomics and Machine Learning in Medical Imaging (9 papers) and Cancer Immunotherapy and Biomarkers (9 papers). Ferry Lalezari is often cited by papers focused on Lung Cancer Diagnosis and Treatment (11 papers), Radiomics and Machine Learning in Medical Imaging (9 papers) and Cancer Immunotherapy and Biomarkers (9 papers). Ferry Lalezari collaborates with scholars based in Netherlands, United Kingdom and United States. Ferry Lalezari's co-authors include Kim Monkhorst, Paul Baas, Vincent van der Noort, Jeltje F. de Vries, Joachim G.J.V. Aerts, Willemijn S.M.E. Theelen, Heike Peulen, Adrianus J. de Langen, Idris Bahce and Daphne W. Dumoulin and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

Ferry Lalezari

30 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non–Small Cell Lung Cancer

2019 651 citations Willemijn S.M.E. Theelen, Heike Peulen et al. profile →
Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers

2019 372 citations Stefano Trebeschi, Silvia Girolama Drago et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ferry Lalezari Netherlands	15	1.0k	1.0k	434	312	170	33	1.7k
Heike Peulen Netherlands	17	983 0.9×	1.1k 1.1×	499 1.1×	276 0.9×	228 1.3×	42	1.8k
Jun‐ichi Nitadori Japan	27	980 0.9×	1.8k 1.7×	478 1.1×	307 1.0×	307 1.8×	61	2.5k
Adrianus J. de Langen Netherlands	24	1.1k 1.1×	1.5k 1.4×	1.0k 2.3×	225 0.7×	174 1.0×	49	2.5k
Panagiotis Balermpas Germany	23	713 0.7×	566 0.6×	352 0.8×	256 0.8×	493 2.9×	115	1.7k
Loïc Verlingue France	14	719 0.7×	463 0.5×	640 1.5×	157 0.5×	276 1.6×	51	1.4k
Dianbin Mu China	18	563 0.5×	496 0.5×	440 1.0×	160 0.5×	335 2.0×	52	1.2k
Aaron T. Wild United States	21	1.3k 1.3×	654 0.6×	273 0.6×	171 0.5×	435 2.6×	53	2.0k
Roshal R. Patel United States	14	596 0.6×	343 0.3×	125 0.3×	237 0.8×	123 0.7×	44	941
Raquibul Hannan United States	28	637 0.6×	1.3k 1.2×	460 1.1×	307 1.0×	356 2.1×	110	2.1k
Youling Gong China	21	534 0.5×	662 0.7×	240 0.6×	101 0.3×	256 1.5×	89	1.4k

Countries citing papers authored by Ferry Lalezari

Since Specialization

Citations

This map shows the geographic impact of Ferry Lalezari's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ferry Lalezari with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ferry Lalezari more than expected).

Fields of papers citing papers by Ferry Lalezari

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ferry Lalezari. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ferry Lalezari. The network helps show where Ferry Lalezari may publish in the future.

Co-authorship network of co-authors of Ferry Lalezari

This figure shows the co-authorship network connecting the top 25 collaborators of Ferry Lalezari. A scholar is included among the top collaborators of Ferry Lalezari based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ferry Lalezari. Ferry Lalezari is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Noort, Vincent van der, Ferry Lalezari, Jeltje F. de Vries, et al.. (2025). Pembrolizumab plus lenvatinib as second-line treatment in patients with pleural mesothelioma (PEMMELA): cohort 2 of a single-arm, phase 2 study. The Lancet Oncology. 26(12). 1676–1684.

Ruysscher, Dirk De, Bart Reymen, Maarten Lambrecht, et al.. (2023). 18F-FDG-PET guided vs whole tumour radiotherapy dose escalation in patients with locally advanced non-small cell lung cancer (PET-Boost): Results from a randomised clinical trial. Radiotherapy and Oncology. 181. 109492–109492. 25 indexed citations

Lalezari, Ferry, Vincent van der Noort, Jeltje F. de Vries, et al.. (2023). Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study. The Lancet Oncology. 24(11). 1219–1228. 8 indexed citations

Hummelink, Karlijn, Vincent van der Noort, Mirte Muller, et al.. (2022). PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC. Clinical Cancer Research. 28(22). 4893–4906. 26 indexed citations

Katz, Sharyn I., Christopher M. Straus, Leonid Roshkovan, et al.. (2022). Considerations for Imaging of Malignant Pleural Mesothelioma: A Consensus Statement from the International Mesothelioma Interest Group. Journal of Thoracic Oncology. 18(3). 278–298. 17 indexed citations

Meerveld-Eggink, A., Niels M. Graafland, Sofie Wilgenhof, et al.. (2022). Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data Assessment. European Urology Open Science. 35. 54–58. 20 indexed citations

Schipper, Luuk J., Kris G. Samsom, Pétur Snæbjörnsson, et al.. (2022). Complete genomic characterization in patients with cancer of unknown primary origin in routine diagnostics. ESMO Open. 7(6). 100611–100611. 15 indexed citations

Schipper, Luuk J., Pétur Snæbjörnsson, Kris G. Samsom, et al.. (2021). 1133P Whole genome sequencing can classify diagnostically challenging tumors. Annals of Oncology. 32. S924–S925.

Gooijer, Cornedine J. de, Vincent van der Noort, Jos A. Stigt, et al.. (2021). Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial. The Lancet Respiratory Medicine. 9(6). 585–592. 28 indexed citations

10.

Heuvel, Michel M. van den, Judi van Diessen, Heike Peulen, et al.. (2020). Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer. Clinical Cancer Research. 27(5). 1256–1266. 39 indexed citations

11.

Disselhorst, Maria, Josine M.M.F. Quispel-Janssen, Ferry Lalezari, et al.. (2019). Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. The Lancet Respiratory Medicine. 7(3). 260–270. 159 indexed citations

12.

Trebeschi, Stefano, Silvia Girolama Drago, Nicolai J. Birkbak, et al.. (2019). Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers. Annals of Oncology. 30(6). 998–1004. 372 indexed citations breakdown →

13.

Burgers, Sjaak A., Robin Cornelissen, Joachim G.J.V. Aerts, et al.. (2019). Switch maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma: A multicenter open label phase II trial (NVALT19). Annals of Oncology. 30. v931–v932. 7 indexed citations

14.

Brown, Sean, Michael J. Dubec, D. Cobben, et al.. (2018). P2.01-15 A Radiologist-Led Training Workshop for MR Based Normal Tissue and Tumour Delineation for Lung Cancer Radiotherapy.. Journal of Thoracic Oncology. 13(10). S670–S670. 1 indexed citations

15.

Quispel-Janssen, Josine M.M.F., Vincent van der Noort, Jeltje F. de Vries, et al.. (2018). Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma. Journal of Thoracic Oncology. 13(10). 1569–1576. 167 indexed citations

16.

Theelen, Willemijn S.M.E., Ferry Lalezari, Michel M. van den Heuvel, Paul Baas, & Heike Peulen. (2017). PUB013 Randomized Phase II Study of Pembrolizumab after SBRT versus Pembrolizumab Alone in Patients with Advanced NSCLC, Preliminary Results. Journal of Thoracic Oncology. 12(1). S1453–S1453. 4 indexed citations

17.

Bydlon, Torre M., Ferry Lalezari, Koen J. Hartemink, et al.. (2017). Optimal endobronchial tool sizes for targeting lung lesions based on 3D modeling. PLoS ONE. 12(12). e0189963–e0189963. 1 indexed citations

18.

Meerveld-Eggink, A., Elisa A. Rozeman, Ferry Lalezari, et al.. (2017). Short-term CTLA-4 blockade directly followed by PD-1 blockade in advanced melanoma patients: a single-center experience. Annals of Oncology. 28(4). 862–867. 11 indexed citations

19.

Voncken, Francine E.M., Berthe M.P. Aleman, Jolanda M. van Dieren, et al.. (2017). Radiation-induced liver injury mimicking liver metastases on FDG-PET-CT after chemoradiotherapy for esophageal cancer. Strahlentherapie und Onkologie. 194(2). 156–163. 13 indexed citations

20.

Hattum, E.S. van, Jean‐Paul P.M. de Vries, Ferry Lalezari, Jos C. van den Berg, & Frans L. Moll. (2007). Angioplasty with or without Stent Placement in the Brachiocephalic Artery: Feasible and Durable? A Retrospective Cohort Study. Journal of Vascular and Interventional Radiology. 18(9). 1088–1093. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact